China is one of the largest producers of pharmaceutical raw materials (PRMs), largely due to its low production costs and large population. China accounts for approximately 70% of global vitamin C output, 70% of citric acid output and 90% of penicillin output. The Pharmaceutical Raw Material Manufacturing industry in China manufactures active pharmaceutical ingredients for further preparation of finished pharmaceutical products. Typical products in the industry include bacteriophage, endocrine products, basic vitamins, sulfanilamide medicine, salicylate, glucose and alkaloids. This industry acts as a bridge between the upstream chemical industry and the downstream medical market. This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares.
Table of Contents
ABOUT THIS INDUSTRY- Industry Definition
- Main Activities
- Similar Industries
- Additional Resources
- Executive Summary
- Key External Drivers
- Current Performance
- Industry Outlook
- Industry Life Cycle
- Supply Chain
- Products & Services
- Demand Determinants
- Major Markets
- International Trade
- Business Locations
- Market Share Concentration
- Key Success Factors
- Cost Structure Benchmarks
- Basis of Competition
- Barriers to Entry
- Industry Globalization
OPERATING CONDITIONS
- Capital Intensity
- Technology & Systems
- Revenue Volatility
- Regulation & Policy
- Industry Assistance
- Industry Data
- Annual Change
- Key Ratios
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Zhejiang NHU Co., Ltd.
- Apeloa Pharmaceutical Co., Ltd.
- The United Laboratories International Holdings Limited
- Joincare Pharmaceutical Group Industry Co., Ltd.
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Methodology
LOADING...
